Neutralising antibodies for PD-1 or its ligand programmed cell death ligand 1 (PD-L1) have already shown promise as an immunotherapy for a range of cancers, including non-small cell lung cancer [94–99], heralding its potential as a target for gene-knockout. This evidence concerns the gene CD274 and non-small cell lung carcinoma.